Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus

This analysis provides an early estimate of the cost-effectiveness of adjunctive exenatide in treating type 2 diabetes mellitus in the United States. Data from pivotal phase III 30-week clinical trials and 52 weeks of their subsequent open-label extension studies (i.e., 82 weeks total) were used to...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Value in health Ročník 11; číslo 1; s. 22 - 33
Hlavní autori:	Minshall, Michael E., Oglesby, Alan K., Wintle, Matthew E., Valentine, William J., Roze, Stéphane, Palmer, Andrew J.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Malden, USA Elsevier Inc 2008 Blackwell Publishing Inc
Predmet:	BYETTA Clinical trials Cost effectiveness Cost-Benefit Analysis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - economics Drug Costs exenatide Glycated Hemoglobin A - drug effects Health Care Costs Humans Hypoglycemic Agents - economics Hypoglycemic Agents - therapeutic use Internal Medicine Lipids Metformin modeling Models, Econometric Monte Carlo Method Peptides - economics Peptides - therapeutic use Sensitivity analysis Sulfonylurea Compounds Time Factors type 2 diabetes Type 2 diabetes mellitus United States Venoms - economics Venoms - therapeutic use cost-effectiveness modeling type 2 diabetes BYETTA exenatide
ISSN:	1098-3015, 1524-4733, 1524-4733
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!